A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice

References

• Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306
   PubMed Web of Science ®Google Scholar
• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34
   PubMed Web of Science ®Google Scholar
• Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528-38
   PubMed Web of Science ®Google Scholar
• Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000;37(4 Suppl 6):14-17
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70
   PubMed Web of Science ®Google Scholar
• Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl 3):33-6
   PubMed Web of Science ®Google Scholar
• Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-25
   PubMed Web of Science ®Google Scholar
• Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-34
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20
   PubMed Web of Science ®Google Scholar
• Hedenus M, Adriansson M, San MJ, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403
   PubMed Web of Science ®Google Scholar
• Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-84
   PubMed Web of Science ®Google Scholar
• Pirker R, Ramlau RA, Schuette W, et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008;26:2342-9
   PubMed Web of Science ®Google Scholar
• Amgen. Aranesp Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/4981/ Last accessed 09 February 2012
   Google Scholar
• Auerbach M, Silberstein PT, Webb RT, et al. Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 2010;85:655-63
   PubMed Web of Science ®Google Scholar
• Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006;24:2290-7
   PubMed Web of Science ®Google Scholar
• Gregory SA. Efficacy of darbepoetin alfa in the treatment of chemotherapy-induced anemia in non-Hodgkin’s lymphoma. Support Cancer Ther 2006;3:232-9
   PubMedGoogle Scholar
• Hernandez E, Ganly P, Charu V, et al. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Curr Med Res Opin 2009;25:2109-20
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707
   PubMed Web of Science ®Google Scholar
• Senecal FM, Yee L, Gabrail N, et al. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer 2005;6:446-54
   PubMedGoogle Scholar
• Van Belle S, Karanikiotis C, Labourey JL, et al. Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy – data from the CHOICE study. Curr Med Res Opin 2011;27:987-94
   PubMed Web of Science ®Google Scholar
• Bittner N, Kipkova A, Móciková H, et al. Current management of chemotherapy-induced anemia with darbepoetin alfa – the apriori study. J Clin Oncol 2011;29: Suppl e19723
   Google Scholar
• Eisterer W, Hussl C, Erb H, et al. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 microg every 3 weeks in anaemic cancer patients receiving chemotherapy. Curr Med Res Opin 2011;27:355-63
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) – Version 2.2011. Available at: www.nccn.org 2011 [Last accessed 12 October 2011]
   Google Scholar
• Steinmetz T, Eggert J, Chatsiproios D, et al. CORRECT, a web-based observational study, shows that darbepoetin alfa is effective in treating chemotherapy-induced anaemia and improves QoL in patients with non-myeloid malignancies. Support Care Cancer 2009;17:1021-22
   Google Scholar
• Pirker R, Collins H, Legg J, Vansteenkiste J. Rate of hemoglobin (Hb) decline from <10 g/dL to <9 g/dL in placebo-treated patients (pts) receiving chemotherapy: a pooled analysis of data from 6 randomized darbepoetin alfa trials. J Clin Oncol 2011;29:Suppl e19637
   Google Scholar
• Pirolli M, Collins H, Hulnick S, Quigley J. Rate of hemoglobin (Hb) decline from <10 g/dL to <9 g/dL by electronic medical-record (EMR) evaluation in community oncology patients (pts) receiving chemotherapy in the absence of erythropoiesis-stimulating agents (ESAs). J Clin Oncol 2011;29:Suppl e19625
   Google Scholar
• Canon JL, Vansteenkiste J, Hedenus M, et al. Transfusion risk in cancer patients with chemotherapy-induced anaemia when initiating darbepoetin alfa therapy at a baseline haemoglobin level of <9 g/dL vs 9 to <10 g/dL versus >10 g/dL: an exploratory analysis of a phase 3 trial. Med Oncol 2011 [Epub ahead of print]; DOI: 10.1007/s12032-011-0103-x
   Google Scholar
• Boccia R, Malik IA, Raja V, et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 2006;11:409-17
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Hedenus M, Gascon P, et al. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level <10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. BMC Cancer 2009;9:311
   PubMed Web of Science ®Google Scholar